Table 1. Baseline characteristics according to peripheral ImmunoCRIT.
| Variables | ImmunoCRIT | p-value | |||
|---|---|---|---|---|---|
| Total (N = 422) | High (N = 230) | Low (N = 192) | |||
| Age (years) | < 70 | 342 (81.0) | 182 (53.2) | 160 (46.8) | 0.273 |
| ≥ 70 | 80 (19.0) | 48 (60.0) | 32 (40.0) | ||
| Sex | Male | 274 (64.9) | 87 (31.8) | 187 (68.2) | <0.001 |
| Female | 148 (35.1) | 143 (96.6) | 5 (3.4) | ||
| Lauren classification | Intestinal | 154 (36.5) | 67 (43.5) | 87 (56.5) | 0.003 |
| Diffuse | 228 (54.0) | 140 (61.4) | 88 (38.6) | ||
| Mixed | 36 (8.5) | 19 (52.8) | 17 (47.2) | ||
| Stage by AJCC 7th | II | 203 (48.1) | 101 (49.8) | 102 (50.2) | 0.059 |
| III | 219 (51.9) | 129 (58.9) | 90 (41.1) | ||
| NLR | Low (<2.5) | 331 (78.4) | 169 (51.1) | 162 (48.9) | 0.016 |
| High (≥2.5) | 82 (19.4) | 54 (65.9) | 28 (34.1) | ||
| PNI | High (≥54) | 189 (44.8) | 121 (64.0) | 68 (36.0) | <0.001 |
| Low (< 54) | 199 (47.2) | 90 (45.2) | 109 (54.8) | ||
| Adjuvant chemotherapy | No adjuvant | 1 (0.2) | 1 (100.0) | 0 (0.0) | 0.312 |
| TS-1 | 361 (85.5) | 196 (54.3) | 165 (45.7) | ||
| Capecitabine + oxaliplatin | 40 (9.5) | 19 (47.5) | 21 (52.5) | ||
| Fluorouracil + cisplatin | 20 (4.7) | 14 (70.0) | 6 (30.0) | ||
AJCC, American Joint Committee on Cancer; NLR, neutrophil to lymphocyte ratio; PNI, prognostic nutritional index; WHO, world health organization; AJCC, American Joint Committee on Cancer.